Investigational drug · Phase 3
KarX-EC
Also called: BMS-986519, Xanomeline Enteric-coated, Xanomeline Enteric
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
9 still active
All registered trials
12
Any phase or sponsor naming "KarX-EC"
First trial start
2025
Jul 10, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KarX-EC", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer Disease
- Alzheimer's Disease
- Irritability Associated With Autism Spectrum Disorder
- Schizophrenia
- Autism-Related Irritability
- Psychosis
- Agitation
Approved drugs for the same conditions: Alzheimer's disease · Schizophrenia · Neurology · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "KarX-EC" as an intervention, largest first.
- A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06937229 · 650 participants (planned) · Start Dec 2, 2025 · Primary completion Jun 22, 2029
Drug: KarXT; KarX-EC · For: Alzheimer Disease; Agitation
Sites: Chandler, Arizona; Scottsdale, Arizona; Anaheim, California · 255 sites in all
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseasePivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06976216 · 586 participants (planned) · Start Jul 14, 2025 · Primary completion Sep 11, 2028
Drug: KarXT; KarX-EC · For: Alzheimer's Disease
Sites: Long Beach, California; Redlands, California; Basalt, Colorado · 119 sites in all
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06976203 · 586 participants (planned) · Start Jul 21, 2025 · Primary completion Sep 11, 2028
Drug: KarXT; KarX-EC · For: Alzheimer's Disease
Sites: Fullerton, California; Irvine, California; Los Angeles, California · 129 sites in all
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07011732 · 426 participants (planned) · Start Jul 10, 2025 · Primary completion Nov 24, 2028
Drug: Xanomeline/Trospium Chloride Capsule; Xanomeline Enteric Capsule and 1 more · For: Alzheimer Disease
Sites: Scottsdale, Arizona; Anaheim, California; Fresno, California · 162 sites in all
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseasePivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07011745 · 426 participants (planned) · Start Jul 16, 2025 · Primary completion Nov 3, 2028
Drug: Xanomeline/Trospium Chloride Capsule; Xanomeline Enteric Capsule and 1 more · For: Alzheimer's Disease
Sites: Chandler, Arizona; Garden Grove, California; Long Beach, California · 143 sites in all
- A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsPivotal-lookingRecruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
NCT07424404 · 400 participants (planned) · Start Apr 7, 2026 · Primary completion Mar 8, 2030
Drug: KarXT; KarX-EC · For: Schizophrenia; Autism-Related Irritability
Sites: Dothan, Alabama; Phoenix, Arizona; Anaheim, California · 105 sites in all
- A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06947941 · 325 participants (planned) · Start Mar 25, 2026 · Primary completion Feb 21, 2028
Drug: KarXT; KarX-EC and 1 more · For: Alzheimer Disease; Psychosis
Sites: Gilbert, Arizona; Chino, California; Naples, Florida · 22 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07063342 · 236 participants (planned) · Start Jun 27, 2025 · Primary completion Mar 29, 2027
Drug: Xanomeline/Trospium Chloride Capsule; Xanomeline Enteric Capsule and 4 more · For: Healthy Volunteers
Sites: Nottingham, United Kingdom
- A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With AutismPivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07284745 · 176 participants (planned) · Start Oct 6, 2026 · Primary completion Aug 6, 2029
Drug: KarXT; KarX-EC and 1 more · For: Irritability Associated With Autism Spectrum Disorder
Sites: Dothan, Alabama; Phoenix, Arizona; Anaheim, California · 41 sites in all
- A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum DisorderPivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07285798 · 176 participants (planned) · Start Oct 6, 2026 · Primary completion Aug 6, 2029
Drug: KarXT; KarX-EC and 1 more · For: Irritability Associated With Autism Spectrum Disorder
Sites: Phoenix, Arizona; Glendale, California; Los Angeles, California · 67 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Alzheimer Disease
- ITI-1284JNJ-99245354Phase 36 trials
Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders
- AXS-05dextromethorphan-bupropionPhase 33 trials
Axsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Smoking Cessation
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- Combined metabolic activatorsPhase 32 trials
ScandiBio Therapeutics AB · Alzheimer Disease, Gout Disease
- DMB-IINN: Latrepirdine, DimebonPhase 32 trials
Bigespas LTD · Alzheimer Type Dementia, Alzheimer Disease, Dementia of Alzheimer Type
- AR1001Phase 31 trial
AriBio Co., Ltd. · Alzheimer Disease
- XTR006[18F]MK 6240, FlorquinitauPhase 31 trial
Sinotau Pharmaceutical Group · Alzheimer Disease, Neurofibrillary Tangle
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.